Doubling Down on Human Epidermal Growth Factor Receptor 2

被引：1
作者：
Krop, Ian [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 14期
关键词：
METASTATIC BREAST-CANCER; TRASTUZUMAB; PERTUZUMAB; PLUS; CHEMOTHERAPY; LAPATINIB;
D O I：
10.1200/JCO.2011.40.1463
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1574 / 1576
页数：3
相关论文
共 14 条
[1]  
[Anonymous], SAN ANT BREAST CANC
[2]   Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].
Baselga, Jose ;
Cortes, Javier ;
Kim, Sung-Bae ;
Im, Seock-Ah ;
Hegg, Roberto ;
Im, Young-Hyuck ;
Roman, Laslo ;
Pedrini, Jose Luiz ;
Pienkowski, Tadeusz ;
Knott, Adam ;
Clark, Emma ;
Benyunes, Mark C. ;
Ross, Graham ;
Swain, Sandra M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119
[3]   Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy [J].
Baselga, Jose ;
Gelmon, Karen A. ;
Verma, Shailendra ;
Wardley, Andrew ;
Conte, PierFranco ;
Miles, David ;
Bianchi, Giulia ;
Cortes, Javier ;
McNally, Virginia A. ;
Ross, Graham A. ;
Fumoleau, Pierre ;
Gianni, Luca .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1138-1144
[4]   Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].
Blackwell, Kimberly L. ;
Burstein, Harold J. ;
Storniolo, Anna Maria ;
Rugo, Hope ;
Sledge, George ;
Koehler, Maria ;
Ellis, Catherine ;
Casey, Michelle ;
Vukelja, Svetislava ;
Bischoff, Joachim ;
Baselga, Jose ;
O'Shaughnessy, Joyce .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130
[5]   Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer [J].
Cortes, Javier ;
Fumoleau, Pierre ;
Bianchi, Giulia Valeria ;
Petrella, Teresa M. ;
Gelmon, Karen ;
Pivot, Xavier ;
Verma, Shailendra ;
Albanell, Joan ;
Conte, Pierfranco ;
Lluch, Ana ;
Salvagni, Stefania ;
Servent, Veronique ;
Gianni, Luca ;
Scaltriti, Maurizio ;
Ross, Graham A. ;
Dixon, Joanna ;
Szado, Tania ;
Baselga, Jose .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) :1594-1600
[6]  
Gianni L, 2010, SAN ANT BREAST CANC
[7]   Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 [J].
Junttila, Teemu T. ;
Akita, Robert W. ;
Parsons, Kathryn ;
Fields, Carter ;
Phillips, Gail D. Lewis ;
Friedman, Lori S. ;
Sampath, Deepak ;
Sliwkowski, Mark X. .
CANCER CELL, 2009, 15 (05) :429-440
[8]   Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells [J].
Konecny, GE ;
Pegram, MD ;
Venkatesan, N ;
Finn, R ;
Yang, GR ;
Rahmeh, M ;
Untch, M ;
Rusnak, DW ;
Spehar, G ;
Mullin, RJ ;
Keith, BR ;
Gilmer, TM ;
Berger, M ;
Podratz, KC ;
Slamon, DJ .
CANCER RESEARCH, 2006, 66 (03) :1630-1639
[9]   A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy [J].
Lee-Hoeflich, Si Tuen ;
Crocker, Lisa ;
Yao, Evelyn ;
Pham, Thinh ;
Munroe, Xander ;
Hoeflich, Klaus P. ;
Sliwkowski, Mark X. ;
Stern, Howard M. .
CANCER RESEARCH, 2008, 68 (14) :5878-5887
[10]  
Lin NU, 2011, J CLIN ONCOL S, V29, p51s
12